Nathan Connell: Transforming Surgical Care with Tranexamic Acid
Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared a post on Linkedln about a recent article by Brett L. Houston et al, published in NEJM, adding:
”Sometimes the most important advances in medicine are not the newest, most expensive therapies.
A new trial published in the New England Journal of Medicine (NEJM Group) highlights the impact of tranexamic acid, or TXA, in major noncardiac surgery.
TXA is a low-cost medication that helps stabilize blood clots and reduce bleeding.
In more than 8,000 patients across 10 hospitals, a hospital-wide TXA policy reduced red blood cell transfusions from 9.8% to 7.4%, without an increased rate of venous thromboembolism at 90 days.
That matters, because it suggests that using TXA in this scenario is a practical, scalable intervention that leads to:
- Fewer transfusions
- Better stewardship of a limited blood supply
- Potential benefit in health systems with constrained resources
Blood transfusion is lifesaving, but blood is also precious. Interventions like TXA remind us that improving outcomes does not always require high-cost technology.
Sometimes it requires using simple, evidence-based tools consistently and thoughtfully.
For patients, clinicians, hospitals, and global health systems, this is exactly the kind of high-value care we should pay attention to.”
Title: Hospital Policy of Tranexamic Acid to Reduce Transfusion in Major Noncardiac Surgery
Authors: Brett L. Houston, Daniel I. McIsaac, Rodney H. Breau, Salmaan Kanji, Peter Greenstreet, Meghan Andrews, Sinziana Avramescu, Hema S. Bagry, Robert Balshaw, Jayesh Daya, Kaitlin Duncan, Christopher C. Harle, Eric Jacobsohn, Tina Kerelska, Marshall Pitz, Paul Komenda, Sarah McIsaac, Tim Ramsay, Tarit Saha, Alan Tinmouth, Angela Recio, Daniel Szoke, Marshall Tenenbein, Sarah Slagerman, Dayna Solvason, Robert Talarico, Dean A. Fergusson, Ryan Zarychanski
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy